Prostatype Genomics AB (publ) (STO:PROGEN)

Market Cap	27.88M -33.7%
Revenue (ttm)	594.00K -69.0%
Net Income	-44.50M
EPS	-1.32
Shares Out	59.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,620
Open	0.5060
Previous Close	0.4730
Day's Range	0.4700 - 0.5440
52-Week Range	0.2800 - 2.2800
Beta	1.48
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Prostatype Genomics AB

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 200...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PROGEN

Financial Performance

In 2025, Prostatype Genomics AB's revenue was 594,000, a decrease of -69.03% compared to the previous year's 1.92 million. Losses were -44.50 million, 8.41% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error